This single tablet regimen is a blockbuster in developed nations that are already saturated with an overabundance of treatment options for HIV-1. There are other effective regimens available, even as a single tablet option, however Biktarvy has been a preferred choice for both 1) new diagnoses and 2) existing cases that are able to transition to a single tablet regimen.
This is a big deal for GILD. If you read my first link, you'll find that in recent years, China has had a significant increase in new diagnoses of HIV. If you didn't already know, when people are recently infected, they are most contagious/infectious within the first 30-40 days.
https://www.avert.org/professionals/hiv-around-world/asia-pacific/china
Submitted August 09, 2019 at 10:39PM by Leroy--Brown https://ift.tt/33rm5xd
